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Summary:
We describe our experience of setting up an allogeneic
BMT program at the Christian Medical College Hospi-
tal, Vellore over a period of 13 years, from October 1986
to December 1999. Two hundred and twenty-one trans-
plants were performed during this period in 214
patients, with seven patients undergoing second trans-
plants. Indication for BMT were thalassemia major –
106 (48%), CML – 30, AML – 35, ALL – 10, SAA – 22,
MDS – six and six for other miscellaneous disorders.
The mean age of this patient cohort was 15.6 years
(range 2–52). Graft-versus-host disease of grades III
and IV was seen in 36 patients (17%) and this was the
primary cause of death in 20 patients (9.2%). All
patients and donors were CMV IgG positive. Sepsis was
the primary cause of death in 16 patients (7.4%), 10
bacterial, four fungal and two viral. One hundred and
ten of this series of patients are alive and disease free
(50%) with a median follow-up of 24 months (range 2–
116). These results are comparable to those achieved for
patients with similar disease status in transplant units
in the Western world and cost a mean of US$15 000.
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Bone marrow transplantation is today a life-saving treat-
ment for many hitherto incurable diseases. In 1997, 17 000
allogeneic and 30 000 autologous bone marrow transplants
had been performed worldwide as estimated by the Inter-
national Bone Marrow Transplant statistical center.1 How-
ever, because of the multidisciplinary high-level support
required, there are only a few centers in the developing
world which are performing bone marrow transplants.
Here, we describe our efforts to develop an allogeneic bone
marrow transplant program and the results achieved.
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Patients and methods
Patient selection
Currently, patients with diseases amenable to BMT who
have the necessary resources and a 6 antigen HLA matched
related donor are considered for BMT. Only about 5% of
the population in India would be able to afford a transplant
either from their own income, insurance, employer or
government.
Methods
Some hospitals in the West perform transplants in standard
single rooms. The much higher level of anti-microbial
resistance2 and poor quality of the environment in
developing countries makes it prudent to have a dedicated
unit where there is a high level of control of the environ-
ment. We have a three-bed positive pressure HEPA filtered
transplant unit and air quality is monitored every month
with blood agar and Saboraud’s dextrose agar settle plates
in each room. All water used for the patient and for the
unit is boiled and cooled. We use dual lumen Hickman
Broviac catheters, which are inserted surgically under
anesthesia.
For thalassemia and other genetic disorders conditioning
has been with busulphan 16 mg/kg or 600 mg/m2 with
cyclophosphamide 50 mg/kg/day for 4 days with or without
anti-lymphocyte globulin. Conditioning for leukemia and
myelodysplastic syndromes has been with the Tutschka
protocol of busulphan 16 mg/kg and cyclophosphamide
120 mg/kg.3 For aplastic anemia we have used various con-
ditioning protocols including the standard Seattle protocol
of cyclophosphamide and ALG.4 Prevention of GVHD has
generally been with cyclosporine and short-term methotrex-
ate.5 The target cyclosporine level is 200–300 ng/ml. Stag-
ing of GVHD has been with the Glucksberg scale.6 GVHD
has been treated with steroids and in severe cases with
anti-T cell monoclonal antibody (OKT3 or IORT3) or
ATG/ALG.
TPN is prepared in house in the transplant unit using
amino acid solutions, dextrose, and electrolytes, trace
elements and vitamins manufactured in India. Lipids are
not given routinely and all TPN is administered using a
Pall 0.22 micron posidyne filter. TPN is started on the day
after the bone marrow has been transfused and stopped
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when the patient is able to take fluids orally: usually
patients receive TPN for 2 weeks. If there is intestinal
GVHD then TPN is administered for prolonged periods.
Acyclovir is administered at a dose of 15 mg/kg/day i.v.
starting day +1 and switched to oral after day 14. This is
continued for 2–3 months as CMV prophylaxis. All patients
and donors are tested for CMV antibodies and if there is
GVHD requiring immunosuppression the patient’s CMV
PCR is checked. If positive, ganciclovir is administered at
doses depending on the blood counts. We currently do not
attempt to sterilize the gut after our initial experience with
fracon and ofloxacin showed that this only resulted in
colonization with resistant coliforms. Our first line anti-
microbial therapy for febrile neutropenia consists of genta-
micin, cefotaxime and fluconazole. If the fever persists or
the patient is toxic this is rapidly escalated to ceftazidime/
imipenem and amoxycillin/clavulinic acid or vancomycin.
We have a high index of suspicion for fungal sepsis based
on our autopsy data7 and the fluconazole is changed to
amphotericin if the fever persists or there is a pulmonary
infiltrate. Stool and throat surveillance cultures are perfor-
med once a week and guide antibiotic policy, particularly
if there are resistant bacteria.
In most cases the stem cell source was bone marrow and
the harvest is taken from the iliac crests with a target
nucleated cell dose of 3 · 108/kg recipient weight. Autolog-
ous blood transfusion is used except for very small donors.
Sternal aspiration needles were used, as in our experience
these produce much less local trauma and very little post-
operative pain. We have not had any cases of needle break-
age. For the occasional obese patient Jamshidi needles are
used. Harvested marrow is collected into a 1-l bag, which
has a 120-micron filter online (Tuta Laboratories, Lane
Cove, Sydney, Australia). Anticoagulation of the harvested
marrow is with ACD (one volume to 7 volumes of marrow)
and preservative free heparin (5000 unit/500 ml of
marrow). The donor is given 25 units/kg of heparin just
before the harvest. All syringes and needles are rinsed with
saline followed by ACD.
For ABO mismatched transplants, initially red cell
depletion was undertaken using the Hemonetics V50 cell
separator but recovery of nucleated cells was poor and
hence we started sedimentation with hydroxyethyl starch at
a ratio of 1:6 HES to marrow volume.8 This procedure is
much easier to perform and in most cases nucleated cell
recovery has been over 90%. In those harvests where the
cell recovery has been poor with gravity sedimentation, the
marrow is reprocessed on the Hemonetics Cell Separator.
For patients with high-titer anti-A or -B antibodies we
reduce the titer by administering donor group plasma.
Engraftment and chimerism are documented by checking
the blood group in a major mismatched transplant. For sex
mismatched transplants monitoring is carried out with an
amylogenin PCR.9 For others VNTR analysis of ApoB,
ACTBP2 or the vonWillebrand gene is carried out. WHO
recommended screening procedures are used in the blood
bank but donors are not screened for CMV since 98% of
the population is sero-positive. Prophylactic platelet trans-
fusion is given if the patient’s platelet count is below
2000/mm3. All patients have dedicated donors available for
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Figure 2 Indications for BMT at CMCH, Vellore.
platelet pheresis to provide single donor platelets when the
blood bank supply is inadequate.
Results
Figure 1 illustrates the year-wise distribution of transplants.
After initial teething problems the program has now
become steady with approximately 30 transplants carried
out each year. After the first transplant for thalassaemia in
1991 there has been a steady increase and more than half
the transplants are for thalassaemia.
Figure 2 illustrates the distribution of patients with
regard to the indication for bone marrow transplantation.
Bone marrow harvests have been performed on 214
donors with ages ranging from 6 months to 50 years. Apart
from mild local pain there have been no major compli-
cations and the donor has been discharged 24 to 48 h after
the harvest.
Figure 3 shows the Kaplan–Meier survival curves for the
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Figure 3 Kaplan–Meier probability of survival for the whole group
excluding thalassemia.
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Figure 4 BMT for thalassemia – EFS with respect to class.
whole group and survival curves for patients with thalasse-
mia are given in Figure 4. Table 1 shows the results of all
patients except for the miscellaneous category.
Thalassemia
Of the 106 patients with thalassemia who were transplanted
only six were class I, 30 class II and 70 class III, reflecting
poor pre-transplant transfusion chelation therapy for
Table 1 Results of bone marrow transplantation
Disease No. M F Disease status CR (%) Follow-up Mortality Relapse
patients/No. (months) (non-relapse)
transplants mean
range
Acute myeloid leukemia 35/36 22 13 CR1: 12, CR2: 9 8 (24) 72 19 8
CR3: 1, R1: 5, 16–106 GVHD: 4, IP: 2
R2: 2, R3: 1, REF: Sepsis: 7, DAH: 2
6 Rejection: 3,
IC Bleed: 1
Chronic myeloid leukemia 30 20 10 CP: 26, AP: 1 14 (46) 30 15 2
BT: 2 4–76 GVHD: 7, IP: 2 one 2nd CR after
Syngeneic: 1 Suicide: 1 DLI
Other: 5
Acute lymphatic leukemia 10 7 3 CR1: 3, CR2: 4 3 (30) 33 3 4
CR3: 1, CR4: 1 4–76 GVHD: 1 IP: 1
R2: 1 Sepsis: 1
Aplastic anemia 22/24 14 8 8 (36) 61 7 7
12–116 Fungal sepsis: 3 Rejection
GVHD: 2 VOD: 1
IC bleed: 1
Myelodysplastic syndrome 8 7 1 RAEB: 4 2 (25) 4 6
RAEBt: 4 3–5 VOD: 1, GVHD: 1
Bleed: 1, Sepsis: 1.
Rejection: 2
Thalassemia 106/110 71 35 Class I 6 4 (66) 26 21 GVHD, 1 IP 0
Class II 30 27 (90) 2–87 32 GVHD 1 IP 1
Class III 70 39 (55) 23 GVHD5, VOD6, 8
IP5, Misc 7
CR = complete remission; R = relapse; REF = refractory disease; CP = chronic phase; AP = accelerated phase; BT = blast transformation;
RAEB = refractory anemia with excessive blasts, (RAEBt = in transformation); VOD = veno-occlusive disease; GVHD = graft-versus-host disease;
IP = interstitial pneumonia; IC = intra-cranial bleed; DAH = diffuse alveolar hemorrhage.
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patients with thalassemia in India. There were 71 males and
35 females. The event-free survival was 66% in class I (two
of the six patients died, one due to grade IV gut GVHD
and the other due to interstitial pneumonia), 90% in class
II and 55% in class III patients with a median follow-up
of 26 months (range 2–87 months). Only one of the four
patients who received a second transplant is surviving free
of disease.
Acute myeloid leukemia
Thirty-five patients with AML were transplanted with only
12 in first remission. Eight (24%) of these patients are alive
and free of disease at a median follow-up of 72 months
(16–106 months). Nineteen (54%) have succumbed to
transplant-related complications, while eight (22%) have
relapsed.
Chronic myeloid leukemia
Of the 30 patients with CML transplanted, 26 were in
chronic phase, one in accelerated phase and two in blast
transformation. There was one syngeneic BMT and this
patient relapsed 24 months post transplant. Fourteen of the
30 patients with CML are in complete hematological
remission (all patients tested so far are also bcr/abl negative
on RT-PCR) with a median follow-up of 30 months (range
4–76). Of the two patients who relapsed, one is now in
remission post-donor leukocyte infusion. GVHD was the
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major cause of mortality (23%). Subset analysis shows that
only three of the first 15 patients with CML transplanted
at Vellore between 1988 and 1996 are alive and free of
disease (20%) while the survival is 73% in the 15 patients
transplanted between 1996 and 1999; this is illustrated in
Figure 5.
Acute lymphatic leukemia
Ten patients have been transplanted with only three in first
remission; three patients are surviving free of disease with a
median follow-up of 33 months (4–76). Four patients have
relapsed, and sepsis, GVHD and interstitial pneumonia
resulted in death in the other three patients.
Aplastic anemia
Twenty-four transplants have been performed in 22 patients
with one of the two patients who received a second trans-
plant being a long-term survivor. Eight of (36%) this cohort
of patients have normal hematopoiesis with a median
follow-up of 61 months (12–116). Rejection has been the
most important cause of failure (31%), the other causes
being fungal sepsis (three), veno-occlusive disease (one),
GVHD (two) and intra-cranial bleeding (one).
Myelodysplastic syndrome
Only two of the eight patients with MDS transplanted are
surviving, but the follow-up in these two patients is short
at 3 and 5 months.
Miscellaneous
There were two patients with Fanconi’s anemia in this
group, 12 and 17 years old, both of whom had received
multiple transfusions before transplant. One was con-
ditioned with total abdominal radiation and low-dose cyclo-
phosphamide and the other with fludarabine, anti-T cell
monoclonal antibody (IORT3) and cyclophosphamide. One
patient failed to engraft while the other, a mother to son
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Figure 5 Kaplan–Meier survival curve in CML patients.
transplant rejected very shortly after initial engraftment.
One patient with myelofibrosis failed to engraft and autopsy
showed extensive tuberculosis and disseminated fungal
infection. A child with Blackfan Diamond syndrome unre-
sponsive to steroids and transfusion dependent received a
graft from his HLA matched grandmother. This child
developed grade IV hemorrhagic cystitis requiring urinary
diversion but is now transfusion free with a stable graft and
mild chronic GVHD 30 months post transplant. One patient
with PNH is now 2 years post transplant with a stable graft,
and a 6-month-old child with Wiskott–Aldrich syndrome is
now 2 years post transplant with a normal platelet count
and immunoglobulin levels.
Discussion
The bone marrow transplant program at the Christian Medi-
cal College Hospital Vellore started in 1986 and the first
patient had AML in third relapse. He failed to engraft,
became colonized with Pseudomonas as a result of
attempted gut sterilization and expired on day 30 with
Pseudomonas septicemia and persistent leukemia. We have
come a long way since then, with many protocols having
been modified to suit local conditions and we now under-
take approximately three transplants a month. We have a
waiting list of 40 patients who have matched sibling
donors, with diseases such as thalassaemia and CML and
we are unable to accommodate all those patients who need
urgent transplantation. We receive requests for BMT from
all the neighboring countries which do not have programs:
Pakistan, Sri Lanka, Bangladesh, Nepal, Bhutan and
Sikkim. This suggests that there is a need to develop bone
marrow transplant facilities in other centers in India and in
neighboring countries.
Bone marrow transplantation today offers an alternative
to life-long transfusion and chelation for patients with thal-
assemia major. In December 1981 the first allogeneic bone
marrow transplant for thalassemia major was performed in
Seattle. That patient is now alive and well 19 years post
transplant.10 The team at Pesaro in Italy under the leader-
ship of Professor Guido Lucarelli has since shown with 805
patients that bone marrow transplantation is in fact a good
alternative to transfusion chelation for thalassemia.11 How-
ever, the procedure is associated with a significant risk of
infection, regimen-related toxicity, GVHD and relapse,
particularly in those patients who, because of inadequate
transfusion and poor chelation, have developed hepato-
megaly and hepatic fibrosis.12 The team in Pesaro has
developed risk stratification based on these three criteria:
class I (well chelated, no hepatomegaly, no hepatic
fibrosis); class II (one to two adverse risk factors); class III
(all three adverse risk factors). In Table 2 data from Pesaro
are compared to the results achieved at CMCH, Vellore.
The 90% disease-free survival in the 30 patients in class II
transplanted in our series is comparable to the best results
achieved anywhere in the world and so is the data in class
III. The number of patients in class I in our series is small
and the loss of two patients illustrates the fact that bone
marrow transplantation is unpredictable in terms of GVHD
and RRT even in good risk patients. The cost of transfusion
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Table 2 Results of bone marrow transplantation in Pesaro, Italy 1997
compared with data from CMCH, Vellore
Class Pesaro Pesaro CMCH CMCH
OS % DFS % OS % DFS %
I 97 93 66 66
II 88 85 90 90
III
pre 1989 54 49 55 44
post 1989 91 60
and chelation with desferrioxamine for 1 year for a 30 kg
child in India is US$5000. The US$15 000 required for a
bone marrow transplant is equivalent to 3 years of trans-
fusion and chelation, and therefore BMT is a cost effective
alternative to life-long transfusion in India.
The results of transplantation in acute myeloid leukemia
are disappointing but considering disease status at trans-
plant with more than half the patients being in second or
subsequent remission or with relapsed and refractory dis-
ease, they are comparable to International Bone Marrow
Transplant data.13 It is possible that peripheral blood stem
cell transplants rather than bone marrow, with more rapid
engraftment and possibly more GVL with reduced relapse
rates will solve our problems of sepsis and relapse in this
group but with more chronic GVHD.14
Chronic myeloid leukemia is the commonest leukemia
among adults in India and allogeneic bone marrow trans-
plantation offers curative treatment.15 For the small subset
of patients who achieve a complete cytogenetic remission
with interferon and therefore are likely to have a prolonged
survival, BMT may not be the first option, particularly if
the patient is older, but the cost of interferon at US$7500
to US$12 000 a year is prohibitive.16 In a report from the
International Bone Marrow Transplant Registry (IMTR) the
3-year probability of leukemia-free survival was 57% for
patients who underwent transplantation in chronic phase
with marrow from HLA-identical siblings between 1987
and 1994.17 Forty percent of all the patients transplanted
with CML at our center are alive and free of disease. If the
patients in accelerated phase (two) and the one patient with
an identical twin donor are excluded the result of 52% is
comparable to IBMTR results. Subset analysis shows that
only three of the first 15 patients with CML transplanted
at Vellore between 1988 and 1996 are alive and free of
disease (20%) while the survival is 73% in the 15 patients
transplanted between 1996 and 1999. This shows clearly
that results improve as the transplant team gains experience
and supportive care infrastructure and technology are
improved. Since 1996 we have been administering
10 mg/kg G-CSF for 2 days prior to harvest to the donor
and this may have also contributed.
We have only eight patients with acute lymphatic leuke-
mia for whom bone marrow transplantation has been per-
formed and many of these have been in second or sub-
sequent remission or in relapse and therefore our result of
30% DFS is comparable to data from the West.18
In patients with aplastic anemia our survival of 36% is
disappointing. Most patients come to transplant after having
Bone Marrow Transplantation
received multiple transfusions. It is well known that rejec-
tion rates are higher in this group.19 Patients with aplastic
anemia in India have many episodes of sepsis before they
come to transplant and in two of our patients activation of
fungal sepsis post transplant has been the cause of death.
If the results of transplantation in aplastic anemia in India
are to improve we need to get patients into transplant early
but the logistics are formidable. Also, prompt treatment of
sepsis and transfusion with only irradiated or leuko-
depleted blood products will reduce rejection.20
The successful transplant of a 6-month, 5-kg baby with
Wiskott–Aldrich syndrome who is now 15 months post
transplant with a normal platelet count and free of sepsis
suggests that the unit has now acquired a reasonably high
level of expertise in bone marrow transplantation.21
BMT in tropical countries poses a significant problem in
terms of unusual infections. All patients transplanted at our
center are positive for CMV IgG, unlike in the West where
over 30% of patients and donors are CMV negative. Docu-
mented biopsy-proven CMV disease was seen in nine
patients (seven intestine, three lung and one both) while
30 patients (13%) became CMV PCR positive in the peri-
transplant period. In those patients with positive blood cul-
tures, gram-negative bacilli were isolated in 75%, with
Pseudomonas species being the commonest (24%). Biopsy-
or culture-proven fungal sepsis (some at autopsy) was seen
in 36 patients (Aspergillus 21, Candida nine, Mucor one
and Zygomycetes one). Three patients developed malaria:
two P. vivax and one P. falciparum: all were successfully
treated. Five patients developed tuberculosis (2.2%). We do
not administer anti-tuberculosis or anti-malarial drugs
prophylactically.
Acute GVHD was seen in 92 patients. The severe form
(grades III and IV) was seen in 36 patients (17%) and this
is similar to data from the West for the mixed cohort of
patients in the group. Chronic GVHD was seen in 35
patients with most being limited. Aggressive histological
documentation where possible, rapid initiation of treatment
and very slow tapering of immunosuppression are some of
the lessons that we have learnt in the management of
GVHD.
For our initial transplants we used only hydration or
Mesna and hemorrhagic cystitis was a significant problem.
However, after using a combination of hydration at 3 l/m2
and Mesna (seven doses at 20% of the dose of
cyclophosphamide), this has ceased to be a major problem.
Veno-occlusive disease related to conditioning with busul-
phan and cyclophosphamide is still a problem, particularly
in class III patients with thalassaemia and this contributes
to the morbidity.
Figure 6 shows that drug and disposables account for
most of the transplant cost. Our first successful transplant
in a 6-year-old girl with CML cost US$2000 in 1988.
Today, the cost ranges from US$6500 for an uncomplicated
transplant in a child to US$40 000 for a complicated trans-
plant in an adult and the actual cost billed to four represen-
tative patients is indicated in the legend which accompanies
the figure.
This study demonstrates that it is possible to develop an
allogeneic bone marrow transplant program in the
developing world with results that are comparable to those
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Disposables
10%
Drugs
41%
Investigations
11%
Physician fees
8%
Room charges
17%
Blood product
13%
UPN
Disease
BSA  M2
Period  Days
Investigations
Physician fees
Room charges
Blood product
Disposables
Total
Drugs
214 229 217 171 Mean
THAL* THAL* CML* CML*
0.9 1.2 1.5 1.66
62 90 43 60
1241 3131 928 1642 1735.50
631 1931 1174 1603 133475
2571 4287 2168 2438 2866.00
1606 5265 228 1349 2112.00
3393 13034 3500 7549 6869.00
1107 2398 511 2346 6362.00
11,152 30,049 8,512 16,930 16666.75
*Uncomplicated
**Complicated
(GVHD, sepsis)
Actual cost of BMT from admission to discharge in US$ for four patients
Figure 6 Cost breakdown of BMT in US dollars.
achieved in the West at a significantly lower cost. The
infrastructure developed for a bone marrow transplant pro-
gram will improve the quality of care in terms of trans-
fusion support, infection control and management of neu-
tropenia in tertiary referral institutions in the developing
world.22
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